We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
+13.3%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$4.83B
AUM Growth
-$193M
(-3.8%)
Cap. Flow
-$2.01B
Cap. Flow
% of AUM
-41.54%
Top 10 Holdings %
Top 10 Hldgs %
42.39%
Holding
141
New
14
Increased
13
Reduced
19
Closed
37
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amylyx Pharmaceuticals
AMLX
|
+$95.6M |
| 2 |
ARS Pharmaceuticals
SPRY
|
+$71.9M |
| 3 |
AMED
Amedisys
AMED
|
+$70M |
| 4 |
Vaxcyte
PCVX
|
+$27.5M |
| 5 |
NewAmsterdam Pharma
NAMS
|
+$24.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$94.9M |
| 2 |
Biogen
BIIB
|
+$88.1M |
| 3 |
AERI
Aerie Pharmaceuticals
AERI
|
+$73.5M |
| 4 |
Pulmonx
LUNG
|
+$62M |
| 5 |
SILK
Silk Road Medical, Inc. Common Stock
SILK
|
+$55.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 56.42% |
| 2 | Financials | 0.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
NUVL
1
DELISTED
Nuvalent
NUVL
| $595M | 12.32% |
19,991,024
+650,000
| +3% | +$18.1M |
|
2
Neurocrine Biosciences
NBIX
$17.2B
| $181M | 3.74% |
1,512,714
| – | – |
|
3
AdaptHealth
AHCO
$1.49B
| $147M | 3.03% |
7,626,914
-596,622
| -7% | -$12.6M |
|
4
Viatris
VTRS
$20.1B
| $111M | 2.3% |
10,000,000
-673,700
| -6% | -$7.04M |
|
|
CPRX
5
DELISTED
Catalyst Pharmaceutical
CPRX
| $109M | 2.27% |
5,884,448
+988,448
| +20% | +$15.2M |
|
|
6
Amylyx Pharmaceuticals
AMLX
$1.97B
| $99.5M | 2.06% |
+2,693,000
| New | +$95.6M |
|
|
AMED
7
DELISTED
Amedisys
AMED
| $94.9M | 1.96% |
1,136,080
+776,315
| +216% | +$70M |
|
|
8
ARS Pharmaceuticals
SPRY
$695M
| $94.5M | 1.96% |
+11,077,927
| New | +$71.9M |
|
|
SILK
9
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| $73.8M | 1.53% |
1,396,640
-1,138,729
| -45% | -$55.5M |
|
|
ISEE
10
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $73.3M | 1.52% |
3,424,852
-819,246
| -19% | -$17.5M |
|
11
Larimar Therapeutics
LRMR
$384M
| $70M | 1.45% |
16,941,357
| – | – |
|
|
CMAX
12
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
| $57.9M | 1.2% |
528,703
| – | – |
|
13
Centene
CNC
$32.8B
| $46.3M | 0.96% |
565,000
+101,000
| +22% | +$8.25M |
|
|
HLVX
14
DELISTED
HilleVax
HLVX
| $45.1M | 0.93% |
2,694,101
+40,870
| +2% | +$738K |
|
15
Phreesia
PHR
$662M
| $44.2M | 0.92% |
1,366,329
+8,329
| +0.6% | +$226K |
|
16
Mirum Pharmaceuticals
MIRM
$7.25B
| $39.6M | 0.82% |
2,032,335
| – | – |
|
|
EHAB
17
DELISTED
Enhabit
EHAB
| $39.4M | 0.82% |
2,996,000
+1,541,721
| +106% | +$20.6M |
|
|
DCPH
18
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $38.5M | 0.8% |
2,349,228
-142,262
| -6% | -$2.31M |
|
|
MRUS
19
DELISTED
Merus
MRUS
| $36.8M | 0.76% |
2,380,438
-141,115
| -6% | -$2.48M |
|
20
AnaptysBio
ANAB
$1.72B
| $36M | 0.75% |
1,161,826
-304,774
| -21% | -$8.61M |
|
21
Edgewise Therapeutics
EWTX
$4.28B
| $35.2M | 0.73% |
3,933,137
| – | – |
|
22
Brookdale Senior Living
BKD
$3.58B
| $34.6M | 0.72% |
12,679,651
+3,987,090
| +46% | +$14.9M |
|
23
Cogent Biosciences
COGT
$6.68B
| $34.3M | 0.71% |
2,966,345
| – | – |
|
|
24
Vaxcyte
PCVX
$8.12B
| $33.6M | 0.69% |
+700,000
| New | +$27.5M |
|
25
IDEAYA Biosciences
IDYA
$3.47B
| $31.7M | 0.66% |
1,743,628
| – | – |
|
Similar funds
FT
GRQ
AV
PCM
VA
QC
IC
NW
Deerfield Management's Q4 2022 Portfolio in Review
As of Q4 2022, Deerfield Management held 141 positions worth $4.83B, down 3.8% from $5.02B the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Deerfield Management withdrew a net $2.01B in Q4 2022, closing 37 positions and reducing 19 holdings. Its most notable exit was Gilead Sciences, an estimated $94.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 56% of assets, up from 53% a quarter earlier, followed by Financials.
Against the trend, Deerfield Management opened a new position in Amylyx Pharmaceuticals worth $99.5M.
- Deerfield Management's largest Q4 2022 buy was Amylyx Pharmaceuticals: 2,693,000 shares worth $99.5M.
- Deerfield Management added most to Amedisys in Q4 2022, an estimated $70M increase.
- Deerfield Management's biggest Q4 2022 reduction was Silk Road Medical, Inc. Common Stock, cutting an estimated $55.5M.
- Deerfield Management fully exited Gilead Sciences in Q4 2022, selling an estimated $94.9M.
- Deerfield Management's ten largest holdings make up 42% of its $4.83B portfolio in Q4 2022.
- Deerfield Management opened 14 new positions and closed 37 in Q4 2022.
- Deerfield Management's portfolio value fell 3.8% quarter-over-quarter to $4.83B.
Based on Deerfield Management's 13F filing for Q4 2022, filed 14 Feb 2023.